Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Subjects

This was a randomized, single‐blind, single‐dose, 3‐arm parallel‐group study. Healthy subjects were randomized to receive ABP 710 (n = 50) or infliximab reference product (RP) sourced from the United States (infliximab US; n = 50) or the European Union (infliximab EU; n = 50) 5 mg/kg intravenously o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Vincent, Oh, MyungShin, Gessner, Melissa A., Fanjiang, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027815/
https://www.ncbi.nlm.nih.gov/pubmed/31628783
http://dx.doi.org/10.1002/cpdd.738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027815/
https://www.ncbi.nlm.nih.gov/pubmed/31628783
http://dx.doi.org/10.1002/cpdd.738

Ejemplares similares